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Aim: We investigated quantitative ultrasound (QUS) in patients with node-positive head and neck ma-
lignancies for monitoring responses to radical radiotherapy (RT). Materials & methods: QUS spectral and
texture parameters were acquired from metastatic lymph nodes 24 h, 1 and 4 weeks after starting RT.
K-nearest neighbor and naive-Bayes machine-learning classifiers were used to build prediction models for
each time point. Response was detected after 3 months of RT, and patients were classified into complete
and partial responders. Results: Single-feature naive-Bayes classification performed best with a prediction
accuracy of 80, 86 and 85% at 24 h, week 1 and 4, respectively. Conclusion: QUS-radiomics can predict RT
response at 3 months as early as 24 h with reasonable accuracy, which further improves into 1 week of
treatment.
Lay abstract: Patients with head and neck cancer are often treated with radiation, which usually spans
over 6–7 weeks. The response is usually measured 3 months after treatment completion. In this study, we
had performed ultrasound scans from the patient’s neck node during radiation treatment (after 24 h, 1 and
4 weeks). Artificial intelligence was used to interpret the ultrasound imaging and predict the response
to radiation at the end of 3 months. The scans obtained after the first week were able to predict the
treatment response with reasonable accuracy (86%).
First draft submitted: 24 April 2020; Accepted for publication: 24 July 2020; Published online:
4 September 2020
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Head and neck (H&N) cancers are a group of malignancies involving sites like the pharynx, larynx, oral cavity, nasal
cavity, salivary glands and paranasal sinuses [1]. H&N cancers are the sixth most common cancers worldwide and are
attributed to 550,000 new cancer diagnoses and 300,000 deaths annually [2]. The majority of H&N malignancies
arise from the epithelial lining of the upper aerodigestive system, with 80–90% being squamous cell carcinomas.
Treatment outcomes are largely dependent on the stage of disease at the time of presentation, etiopathogenesis and
other factors such as smoking, human papillomavirus, patient performance status and compliance to treatment. Ap-
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proximately 60% of patients are diagnosed with advanced-stage disease, often with metastatic regional lymph node
(LN) involvement [1,3]. Radical radiotherapy (RT) comprises the standard of care for a significant group of patients
with head and neck squamous cell carcinoma combined with concurrent systemic therapy (chemotherapy/targeted
therapy) and results in excellent organ preservation rates [4,5]. Surgery forms the primary treatment for patients
with malignancies involving the oral cavity or advanced pharyngeal/laryngeal tumors with cartilage erosion, or for
patients having residual disease postRT.
Response following RT is assessed with imaging and clinical examination 10–12 weeks following RT comple-
tion [6,7]. Tumor size change is often a delayed manifestation resulting from the accumulation of cell death and
microstructural changes within the treated tumor [8]. Monitoring treatment response at an early stage during treat-
ment is of clinical interest to enable response-guided personalized therapy and consequently to improve survival
outcomes and to decrease treatment-related toxicities. In recent years, advanced imaging analysis has been made
possible with the introduction of computer vision and machine-learning algorithms, commonly recognized as the
field of ‘radiomics’. Artificial intelligence helps interpret complex data and correlation with clinical end points.
Computational analysis of imaging leads to the generation of multidimensional complex features from which
simplified models are developed using machine-learning-based classifiers. In the study here, K-nearest neighbor
(K-NN) and naive-Bayes algorithms were used for classification, using clinical treatment response as ground truth
labels. A K-NN classifier can perform classification by determining the majority class of the K-NNs to an unlabeled
data point, where K is a positive integer. The K-NNs are determined by computing the distance between the
unlabeled data point and its neighbors. Similarly, a naive-Bayes methodology can be used to classify data using
Bayes’ theorem. This classifier assumes that all of the input features are independent of one another.
For H&N malignancies, several studies have demonstrated the efficacy of radiomic analysis for different imaging
modalities like computed tomography (CT), MRI and PET in predicting outcomes [9,10]. Quantitative ultrasound
(QUS) can detect changes in tumor microstructure during treatment. These changes reflect variations in acoustic
properties related to ongoing cell death via apoptosis as well as other changes in the tissue microstructure [11,12].
Clinical studies in patients with locally advanced breast cancer (LABC) have demonstrated that changes in QUS
parameters early into neoadjuvant chemotherapy (NAC) can be used to predict treatment response [13–15]. Being an
inexpensive, nonionizing and portable imaging modality, QUS has the potential to be used for the early detection of
H&N tumor response to treatment. In this report, we present the results from the first clinical study investigating
the role of QUS imaging data obtained during radical RT for patients with H&N malignancies in predicting
long-term tumor response early after the start of RT.
Materials & methods
Patients
The human study protocol employed in this research was approved by the institutional research ethics board
at Sunnybrook Health Sciences Centre, Toronto, Canada (ClinicalTrials.gov Identifier NCT03908684). After
obtaining written informed consent, patients with a confirmed diagnosis of H&N carcinoma at their primary disease
site or neck nodes (for carcinoma with unknown primary) were recruited for study participation. Specialist H&N
pathologists tested for histological confirmation of disease, and additional tests were done to determine human
papillomavirus or Epstein–Barr virus involvement [16–18], as part of the standard of care following institutional
guidelines [19]. None of the patients included in the current analysis exhibited nonresponse to treatment. No
patients had stable disease or progressive disease (nonresponder) within the first 3 months of treatment completion.
As part of the patients’ diagnostic workup, a pretreatment CT and MRI were completed for disease staging (along
with PET-CT in selected patients as indicated clinically), which provided information regarding LN involvement
and size. Patient disease, treatment characteristics and clinical outcomes were obtained from a prospectively
maintained database and through electronic medical records, treatment planning systems and imaging. All patients
were treated with radical RT using conformal image-guided techniques (intensity modulated RT) as per institutional
practice, with 70 Gy/33 fractions delivered over 7 weeks to high-risk target volumes (primary and nodes). The use
of concurrent systemic therapy was at the discretion of the responsible medical oncologist according to standard
institutional practice.
Treatment response evaluation
As part of the patients’ post-treatment response evaluation, MRI (with or without CT/PET-CT as decided by
treating physicians) was acquired 3 months after the final dose of RT. Radiological end points were evaluated for the
10.2144/fsoa-2020-0073 Future Sci. OA (2020) FSO624 future science group
QUS in response monitoring for head-neck malignancies Research Article
primary site and LN, based on standard response criteria in solid tumors (RECIST 1.1) [20]. Complete responders
(CR) were defined as having a complete resolution of the primary tumor and for all pathologically enlarged LN
measuring <10 mm (short axis), with others classified as partial responders (PR). None of the patients included in
the analysis were nonresponders (either no response or progressive disease) during RT or at 3 months at the primary
tumor site or associated nodes. Additional information, if available through histology or metabolic imaging, was
used to supplement classification into CR or PR categories at 3 months.
Ultrasound data acquisition
The treating radiation oncologist determined the index LN for individual patients as the largest or most prominent
node clinically. An ultrasound scan of the target index LN was acquired immediately before starting RT and at
24 h, week 1 and 4 of patient treatment. Ultrasound radiofrequency (RF) data collection was performed by an
experienced research sonographer using a custom-built ultrasound device (Elekta Ltd, Montreal, Canada) equipped
with a linear 4D transducer (4DL14-5/38 Linear 4D, BK Ultrasound, MA, USA), which had a center frequency
of approximately 8 MHz and a sampling rate of 40 MHz. Data were acquired along 256 lateral scan lines (3.8 cm
lateral field of view) with a scan depth of 5 cm and focus depth of 2.5 cm. The transducer was focused on the
midline of the enlarged LN, and RF data were acquired across the entire LN volume.
QUS features
QUS spectral analysis was completed over a region of interest, spanning the entire volume of the target LN. Spatial
parametric images were generated for each QUS parameter by applying a sliding window analysis technique with a
2 × 2 mm sliding window and a 94% overlap between the adjacent windows in both the axial and lateral directions.
Seven QUS parameters were computed using spectral analysis: mid-band fit, spectral slope (SS), spectral intercept
(SI), attenuation coefficient estimate (ACE), spacing among scatterers (SAS), average scatterer diameter (ASD) and
average acoustic concentration (AAC). In order to nullify the effects of system transfer functions and beamforming
by the transducer, normalization was performed using reference data obtained with the same patient scan settings
from a tissue-mimicking phantom. The phantom was comprised of 5–30 μm glass beads enclosed in a homo-
geneous medium of microscopic oil droplets, which were immersed in gelatin with an attenuation coefficient of
0.576 dB/MHz/cm and a speed of sound of 1540 m/s (Department of Medical Physics, University of Wisconsin,
WI, USA). The mid-band fit, SS and SI parameters were derived by performing a linear regression over the mean
log-compressed, attenuation-compensated, normalized power spectrum [21]. Attenuation correction was achieved
using the point-compensation method [22] by estimating the ACE, adopting the reference phantom technique [23].
The ASD and AAC parameters were derived by fitting a spherical Gaussian form factor model to the backscatter
coefficient computed using an attenuation-corrected normalized power spectrum. The SAS parameter was obtained
by applying an autoregressive model onto the power spectrum of the sample, where the model parameters were
computed employing the Burg’s recursive algorithm [24].
The mean values of QUS parameters were determined by averaging QUS parametric image pixel values.
Texture features
Second-order statistical analyses were performed on QUS parametric maps using a grey-level co-occurrence (GLCM)
technique [25], which represents the angular relationship and distances between neighboring pixels in QUS para-
metric maps. Further details and the interpretation of various GLCM features have been discussed in previous
studies [25,26]. For each QUS parametric map, 16 GLCMs were constructed at four interpixel distances (1, 2, 3 and 4
pixels) and four directions (0, 45, 90 and 135◦). Four textural features were determined from each QUS parametric
map and were comprised of GLCM contrast (CON), correlation (COR), energy (ENE) and homogeneity (HOM)
values.
At each experimental assessment time, seven QUS and 24 texture features were obtained (texture analysis was
not performed for ACE), leading to a total of 31 features. For analysis and development of the radiomics model, the
changes in the values for individual features at the fixed scan assessment times (24 h, week 1 and 4) were computed
by subtraction of the values obtained from baseline before starting RT. In the following sections, specific features
are referred to as the differences from baseline rather than the absolute values, unless otherwise specified. As the
values that were used in building the classifiers were the differences at various time points, the radiomics models
used here were based on delta-radiomics.
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Statistical analysis
A Shapiro–Wilk test was conducted to determine the distribution of data for the different parameters. The normally
distributed parameters were tested using an independent sample t-test (two sided, 95% CI) in order to investigate
the differences between PR and CR. Other parameters were tested with the Mann–Whitney U-test (two sided,
95% CI). A Kaplan–Meier product-limit method was used to determine the survival analysis, and a log-rank test
was conducted for univariate analysis. These statistical tests were performed on SPSS V.22 (IBM Corporation, NY,
USA). The threshold for significance was set to p < 0.05.
Classification modeling
K-NN and naive-Bayes algorithms were used for classification, using clinical treatment response as ground truth
labels. Mean QUS and texture parameters were used as classifying features. In order to ensure optimal performance of
the model and to prevent overfitting, only a few selected parameters were used as features in classification processes.
In order to mitigate the curse of dimensionality, the maximum number of features used in the classification was set
to three based on the rule of thumb (number of subjects/10). The best features were acquired through sequential
forward selection in a wrapper framework. This method uses leave-one-out cross-validation to select features, which
results in the highest prediction accuracy. Multivariable class analysis was also tested and compared with the single-
feature model. Up to three of the best features were picked, and class analysis was performed. Based on the results,
the performance of the classifier was evaluated by determining the sensitivity (%), specificity (%) and accuracy
(% Acc). A receiver operator characteristic curve was generated, and the area under the curve was calculated. For
the feature determination and machine-learning classifiers, MATLAB (R2016a, MathWorks, MA, USA) was used.
Results
Patient, disease & treatment characteristics
A total of 36 patients (33 males and three females) were included in this analysis. The median age was 60 years
(range 40–82 years). As defined earlier, response assessment at 3 months following treatment completion was taken
as an end point, which revealed 14 patients to be CR, and the remaining 22 to be PR. Details for clinical and
treatment parameters are presented in Table 1. Concurrent chemotherapy was given along with RT in 30 (83%)
patients, while one (3%) received cetuximab.
Clinical outcomes
The median follow-up for all patients was 32 months (range 12–57 months). Disease recurrence was seen in
nine patients (one had local recurrence, one had regional recurrence in neck nodes, others had distant metastases
with or without locoregional relapse), of which two patients were from the CR group, and the remaining seven
patients were from the PR group. Three-year recurrence-free survival for CR and PR patient groups was 84 and
72%, respectively (p = 0.042). Figure 1 displays the survival plots determined for the two groups.
Feature analysis & classification results
Ultrasound B-mode images and corresponding SI, SAS and ASD parametric maps of patients from each of the
response groups are presented in Figure 2. Two texture features at 24-h post-treatment, SI-ENE and SAS-HOM
were found to be statistically different between CR and PR with p-values of 0.044 and 0.021, respectively, as noted
in Table 2. One QUS texture parameter, ASD-COR, was trending toward significance (p = 0.056). Scatter plots
of all the QUS mean value and textural parameters obtained for CR and PR at 24-h post the first fraction of RT
are presented in Supplementary Figure 1. At other time points, no other features were found to have different
distribution between the two groups.
The classification results obtained using K-NN and naive-Bayes algorithms are displayed in Table 3. Overall,
the univariate naive-Bayes model performed best in predicting treatment response at all assessment times. For the
24-h time point, the change in the AAC (AAC-CON) feature demonstrated a classification Acc of 80%. Acc of
86 and 85% were demonstrated at week 1 and 4 of treatment for the change in SS (SS-COR) and the change in
ACE (ACE), respectively.
For the K-NN classifier, multifeature models improved the classification Acc at week 4 of RT. For one-feature
classification models, the change in ASD (ASD-ENE) resulted in a classification Acc of 77 %. With two features,
the Acc increased to 79 % (SS-ENE + ASD-ENE) and using three features (SS-ENE + SI-ENE +
ASD-ENE) increased the Acc to 80 %. Figures 3, 4 & 5 represent the receiver operator characteristic curves for
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Table 1. Patient, disease and treatment characteristics for the study participants.
Patients and tumor characteristics n = 36 (all subjects) n (%)
Age (years)
Median (range) 60 (40–82)
Sex
Males
Females
33 (92)
3 (8)
Site
Oropharynx
Larynx
Hypopharynx
Left parotid
Nasopharynx
Carcinoma unknown primary
26 (72)
4 (11)
2 (6)
1 (3)
1 (3)
2 (5)
Human papillomavirus
p16+
p16-
Not specified/unclear
24 (67)
1 (3)
11 (30)
Stage
Primary tumor (T)
T0
T1
T2
T3
T4
2 (5)
9 (25)
15 (42)
5 (14)
5 (14)
Node involvement (N)
N1
N2
N3
21 (58)
10 (28)
5 (14)
Systemic therapy
Chemotherapy
Cisplatin (high and low dose)
Carboplatin
Carboplatin + etoposide
Cisplatin + carboplatin
25 (69)
1 (3)
2 (5)
2 (5)
EGFR inhibitor
Cetuximab
1 (3)
None 5 (14)
Response at 3 months
Treatment response classification
CR
PR
14 (39)
22 (61)
CR: Complete responders; EBV+: Epstein–Barr virus-positive carcinoma; N: Nodal staging (AJCC 8th edition); p16+: Human papillomavirus-positive tumor; PR: Partial responders; T: Primary
tumor staging (American Joint Committee on Cancer [AJCC] 8th edition).
Table 2. Twenty four-hours post-treatment quantitative ultrasound mean spectral and texture values for the most
significant features demarcating complete responders from partial responders.
Parameter p-value CR (mean ± SEM) PR (mean ± SEM)
SI-ENE 0.044 0.002 ± 0.001 -0.004 ± 0.030
SAS-HOM 0.021 0.001 ± 0.002 -0.035 ± 0.030
ASD-COR 0.056 0.010 ± 0.008 -0.047 ± 0.038
Bolded parameters demonstrate statistical significance. Other features approach near significance.
ASD: Average scatterer diameter; CR: Complete responders; COR: Correlation; ENE: Energy; HOM: Homogeneity; PR: Partial responders; SAS: Spacing among scatterers; SEM: Standard
error of the mean; SI: Spectral intercept.
naive-Bayes and K-NN classification models using one, two and three features from QUS data acquired at 24 h,
week 1 and 4 of treatment, respectively.
Discussion
In the past several decades we have witnessed a paradigm shift in the management of H&N malignancies, with
radical RT recognized as the standard of care along with concurrent chemotherapy for primary tumors of the
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Figure 1. Kaplan–Meier survival plot showing recurrence-free survival for the complete responder and partial
responder.
pharynx and larynx. These have led to better organ preservation rates as critical functions like swallowing, speech
and breathing are co-ordinated through H&N anatomical structures. The introduction of intensity-modulated RT
and image guidance has further helped in the alleviation of normal tissue toxicities like xerostomia [27]. Despite
these advancements, a significant proportion of patients develop disease recurrence, and most patients cured of
the disease continue to suffer long-term treatment-related toxicities affecting their quality of life [28,29]. This has
spurred the development of useful biomarkers that can be used to monitor cell death in real time while a patient
is undergoing treatment and to predict their overall treatment response. Subsequent personalized risk-adapted
treatments can lead to appropriate radiation dose escalation or de-escalation strategies designed to find the optimal
balance between cure and toxicities based on an individualized approach. Our study is the first clinical report
of using QUS delta-radiomics during RT, as a simple, rapid, inexpensive imaging modality to predict treatment
response to radical RT for H&N malignancies. Delta-radiomics denote the changes of radiomic features over time
associated with tumor changes resulting from treatment. Delta-radiomics determined from QUS imaging data
has previously been demonstrated to be an effective strategy to study and predict the response to NAC in breast
cancer [14].
Using naive-Bayes classification, single-feature selection performed best for all time points in this study compared
with multiple feature selection. At 24 h after the start of radiation, the best feature was found to be the change in
the CON of the AAC parametric map (AAC-CON). This may be due to early changes in the concentration of
scatters. At week 1, the change in the COR of the SS (SS-COR) was the best feature. The SS is related to scatterer
shape and size [11,30,31]. In a previous study, SS has also been found to closely correlate with cell death through the
production of apoptotic bodies and nuclear fragmentation [32]. The change in SS may be due to cell fragmentation
or changes in the structure of the cell’s nucleus. A preclinical study by Vlad et al. found that SS and ultrasound
integrated backscatter parameters changed when tumors were exposed to radiation [33]. Four weeks after the start
of RT, the best classifying feature was the change in the ACE (ACE). The attenuation coefficient is related to the
composition and density of the tissue [34]. This feature has been used in other studies to differentiate fatty from
healthy liver tissue and as a quantitative descriptor in breast masses [35,36].
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Figure 2. QUS Parametric maps. Representative QUS parametric image overlays of SI, SAS and ASD at baseline,
24 h, week 1 and 4 of treatment for a complete responder (A) and a partial responder (B). The ultrasound B-mode
images have been contoured to delineate the lymph node that was scanned.
ASD: Average scatterer diameter; QUS: Quantitative ultrasound; SAS: Spacing among scatterers; SI: Spectral intercept.
Using the K-NN classifier, the single-feature analysis performed best with week 1 data (SAS-ENE), while
multifeature analysis performed best with data acquired at 24 h (SS + AAC-CON) and in week 4 (SS-ENE
+ ASD-ENE) QUS data. The features that were selected mainly involved texture features derived from parametric
maps related to scatterer size, concentration and scatterer spacing.
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Table 3. Results for the best single-feature (A), two-feature (B) and three-feature (C) prediction models generated
from machine-learning algorithms, K-nearest neighbor and naive-Bayes at 24-h post the first radiation treatment,
week 1 and 4 of treatment.
A: single-feature classification
Classifier model Time point %Sn %Sp AUC %Acc Best univariate feature
naive-Bayes 24 h 77 83 0.67 80 AAC-CON
Week 1 85 86 0.77 86 SS-COR
Week 4 84 85 0.79 85 ACE
K-NN 24 h 75 70 0.74 72 AAC-CON
Week 1 75 85 0.81 81 SAS-ENE
Week 4 76 79 0.80 77 ASD-ENE
B: two-feature classification
Classifier model Time point %Sn %Sp AUC %Acc Best two features
naive-Bayes 24 h 67 73 0.64 70 MBF + AAC-CON
Week 1 76 84 0.67 80 SS + AAC-COR
Week 4 75 77 0.75 76 ACE + ASD
K-NN 24 h 74 78 0.78 76 SS + AAC-CON
Week 1 73 78 0.77 76 SS + SAS-ENE
Week 4 76 82 0.81 79 SS-ENE + ASD-ENE
C: three-feature classification
Classifier model Time point %Sn %Sp AUC %Acc Best three features
naive-Bayes 24 h 63 69 0.63 66 MBF + SAS-CON + AAC-CON
Week 1 68 78 0.65 73 SS + SS-COR + AAC-ENE
Week 4 66 64 0.61 65 MBF + ACE + ASD
K-NN 24 h 71 76 0.76 77 SS + SI-ENE + AAC-CON
Week 1 73 81 0.75 77 SS + MBF-ENE + SAS-ENE
Week 4 79 80 0.82 80 SS-ENE + SI-ENE + ASD-ENE
AAC: Average acoustic concentration; Acc: Accuracy; ACE: Attenuation coefficient estimate; ASD: Average scatterer diameter; AUC: Area under curve; CON: Contrast; COR: Correlation;
ENE: Energy; HOM: Homogeneity; K-NN: K-nearest neighbor; MBF: Mid-band fit; SAS: Spacing among scatterers; SI: Spectral intercept; Sn: Sensitivity; Sp: Specificity; SS: Spectral slope.
Statistical analysis of changes in the mean and texture parameters indicated that the SI-ENE and SAS-HOM
at 24 h after the initial treatment were the only parameters that were found to be significantly different between
CR and PR. The 24-h SI-ENE parameter was greater for CR compared with PR. The SI parameter is related to
the scatterer size and composition in tissue microstructure [37,38]. This suggests that there is more significant order
in tissue structure of the LN 24 h after initial treatment for CR compared with PR. The PR demonstrated a lesser
SAS-HOM compared with CR. This may reflect less HOM in the spacing among the scatterers in the LN for
PR.
The role of QUS in medicine and oncology is emerging with previous studies demonstrating QUS as an effective
modality for the monitoring of treatment response in patients with LABC receiving NAC. Sannachi et al. found that
a combination of mean QUS spectral, texture and molecular features was able to classify CR, PR and nonresponders
at 1, 4 and 8 weeks into chemotherapy with Acc of 78, 86 and 83%, respectively [14]. That study found that changes
in scatterer (lobule) spacing (SAS) occurred early on in week 1 after the start of NAC, and changes in the size of
scatterers (lobules) occurred later in week 4. Tadayyon et al. also used pretreatment QUS data to predict LABC
patient response to NAC with an Acc of 88 % [15]. QUS has also been shown to differentiate between benign and
malignant tissue and to classify tumor grade with high Acc [39,40]. Furthermore, a previous study had shown that
preradiation QUS data could predict response at 3 months with an Acc of 88% in H&N malignancies [41]. Although
traditional B-mode ultrasound has been used in the assessment of morphological changes of neck nodes in H&N
malignancies, the application of QUS can provide quantitative data to better estimate the ongoing treatment-related
changes.
Radiomic analysis has been undertaken using other imaging modalities to assess treatment response and clinical
outcomes for different H&N malignancies [42]. A study by Vallie`res et al. used PET-CT to evaluate risks for
recurrence in H&N cancer using texture, shape, intensity and genomic features [10]. Dynamic contrast-enhanced
MRI has been used to predict response in patients with H&N cancer. Cao et al. distinguished patients controlled
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Figure 3. Results for the best single-, two- and three-feature classification using naive-Bayes and K-nearest
neighbor classifier models at 24 h after the initial radiation therapy treatment (receiver operating characteristic
curve presented).
AUC: Area under the curve; CON: Contrast; ENE: Energy; K-NN: K-nearest neighbor; MBF: Mid-band fit; SAS: Spacing
among scatterers; SI: Spectral intercept; SS: Spectral slope.
at the primary site from ones having disease relapse by analyzing the tumor blood volume and flow pretreatment at
2 weeks into treatment [43]. In another study by King et al., diffusion-weighted MRI (DW-MRI) was used to measure
the apparent diffusion coefficient, which demonstrated a significant decrease of the apparent diffusion coefficient
2 weeks after the start of RT [44]. Imaging is crucial in the determination of treatment outcomes. Studies used
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Figure 4. Results for the best single-, two- and three-feature classification using naive-Bayes and K-nearest
neighbor classifier models at week 1 of radiation treatment (receiver operating characteristic curve presented).
AUC: Area under the curve; CON: Contrast; COR: Correlation; ENE: Energy; K-NN: K-nearest neighbor; MBF: Mid-band
fit; SAS: Spacing among scatterers.
DW-MRI and perfusion-weighted MRI to detect recurrent H&N cancer and to differentiate from postradiation
changes [45–47]. PET-based response monitoring showed blood flow parameters to be accurate predictors of metabolic
response [48]. Relative factors to consider for those imaging modalities include their cost, scan duration, radiation
exposure (CT/PET), the need for contrast agents and related toxicities. Ultrasound has the benefit of being relatively
low cost, does not emit ionizing radiation and does not require the administration of exogenous contrast agents
resulting in potentially better patient compliance. This is the first radiomics study involving an RF-based modality
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Figure 5. Results for the best single-, two- and three-feature classification using naive-Bayes and K-nearest
neighbor classifier models at week 4 of radiation treatment (receiver operating characteristic curve presented).
ACE: Attenuation coefficient estimate; ASD: Average scatterer diameter; AUC: Area under the curve; CON: Contrast;
ENE: Energy; K-NN: K-nearest neighbor; MBF: Mid-band fit; SI: Spectral intercept.
like ultrasound using the change in QUS parameters during RT to predict treatment response in H&N patients.
The work identifies that QUS is capable of detecting changes in tissue microstructure as early as 24 h into treatment.
This motivates the use of ultrasound as a technique to monitor the LNs of H&N patients and as a method to
evaluate treatment efficacy.
The imaging target in this study was the largest metastatic LN, which was used to demonstrate that changes in
the biological structure of the LN following RT correlate with patient response to RT. LN response has been shown
to correlate with locoregional control in patients receiving RT for H&N cancer [49,50]. Hauser et al. demonstrated
that the DW-MRI parameter associated with the vascular and perfusion signal in metastatic H&N LNs was able to
distinguish between patients with and without locoregional control after RT treatment [49]. Goguen et al. identified
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a correlation between positive LNs and decreased overall survival and progression-free survival in patients after
receiving chemotherapy and RT [51]. In the study here, although a proportion of the patients were having relatively
lesser follow-up, a significant difference of recurrence-free survival was seen between the CR and PR.
The advantage of QUS-radiomics is the development of biomarkers from a noninvasive imaging modality.
Rapid-scan acquisition and excellent patient compliance make it an attractive strategy, as treatment response can
be monitored in real time early in the course of treatment.
Limitations
There are a few limitations to the work conducted here. First, the primary tumor site was not imaged as these
are structures located at depths within the body that are not accessible by ultrasound imaging. Nonetheless, it is
promising that features from bulky LNs by themselves can predict the overall response of both the primary disease
and the disease in LNs. Additionally, given this was a pilot study to explore feasibility and acquire preliminary
results, the number of patients included in this report has been relatively small. With promising initial results, the
acquisition of additional data will lead to greater confidence in the interpretation of the results. Further expansion
of the study cohort to include patients from other institutions, and independent external validation, will help in
testing the utility of the current feature set with the development of a reproducible feature set. More recent work
has examined interinstrument variability as well as interuser variability and found those sources of variance are not
significant [52].
Conclusion
QUS delta-radiomics has the potential to assess treatment response early in the course of therapy. QUS data
obtained as early as 24 h after starting RT can predict response at 3 months with an Acc of 80%. Additional features
obtained at week 1 and 4 of RT further improved the prediction rates to 85% approximately. Being a relatively
inexpensive, portable and simple imaging modality, QUS-radiomic signatures should be further investigated as an
option to monitor cell death and treatment response in patients with H&N malignancies treated with radical RT.
Future perspective
Future developments could include incorporating QUS-radiomic prediction models in guiding treatment escalation
and de-escalation based on real time response during RT. Additionally, classification performances can potentially
be improved through additional imaging analysis accounting for changes in tumor shape, grey-level histograms
and using other methods of texture analysis as well as integration with clinical and genomic markers [53]. Finally,
once more data are acquired, more advanced machine-learning algorithms such as deep-learning methods, could
be tested for their response assessment capability.
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Executive summary
Background
• This study investigated the use of quantitative ultrasound (QUS) delta-radiomic biomarkers to predict treatment
response in patients with head and neck (H&N) cancer treated with radical radiotherapy (RT).
Materials & methods
• Thirty six patients with node-positive H&N cancer underwent ultrasound imaging of metastatic lymph nodes at
24 h, 1 and 4 weeks after starting RT.
• QUS spectral and texture parameters were extracted from the ultrasound data.
• Machine-learning algorithms were used to develop response prediction models.
Results
• Using the na ve-Bayes classification algorithm, the response prediction accuracies were 80, 86 and 85% using
QUS features acquired at 24 h, 1 and 4 weeks into RT, respectively.
Conclusion
• QUS delta-radiomics was used to predict treatment response to radical RT in H&N malignancies with reasonable
accuracy. The best results were obtained after 1 week of treatment.
References
Papers of special note have been highlighted as: • of interest; •• of considerable interest
1. Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. Lancet 371(9625), 1695–1709 (2008).
2. Jemal A, Bray F, Ferlay J. Global cancer statistics: 2011. CA Cancer J. Clin. 49(1), 33–64 (1999).
3. Olsen MH, Bøje CR, Kjær TK et al. Socioeconomic position and stage at diagnosis of head and neck cancer: a nationwide study from
DAHANCA. Acta Oncol. 54(5), 759–766 (2015).
4. Department of Veterans Affairs Laryngeal Cancer Study group. Induction chemotherapy plus radiation compared with surgery plus
radiation in patients with advanced laryngeal cancer. N. Engl. J. Med. 324(24), 1685–1690 (1991).
• One of the first practice-changing clinical trials establishing the role of definitive radiation with chemotherapy resulting in organ
preservation for head and neck malignancies.
5. Forastiere AA, Goepfert H, Maor M et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal
cancer. N. Engl. J. Med. 349(22), 2091–2098 (2003).
6. Saito N, Nadgir RN, Nakahira M et al. Post-treatment CT and MR imaging in head and neck cancer: what the radiologist needs to
know. Radiographics 32(5), 1261–1282 (2012).
7. Wray R, Sheikhbahaei S, Marcus C et al. Therapy response assessment and patient outcomes in head and neck squamous cell carcinoma:
FDG PET Hopkins criteria versus residual neck node size and morphologic features. Am. J. Roentgenol. 207(3), 641–647 (2016).
8. Brindle K. New approaches for imaging tumour responses to treatment. Nat. Rev. Cancer. 8(2), 94–107 (2008).
9. Wong AJ, Kanwar A, Mohamed AS, Fuller CD. Radiomics in head and neck cancer: from exploration to application. Transl. Cancer Res.
5(4), 371–382 (2016).
10. Vallie`res M, Kay-Rivest E, Perrin LJ et al. Radiomics strategies for risk assessment of tumour failure in head-and-neck cancer. Sci. Rep.
7(1), 10117 (2017).
11. Czarnota GJ, Kolios MC, Abraham J et al. Ultrasound imaging of apoptosis: high-resolution noninvasive monitoring of programmed cell
death in vitro, in situ, and in vivo. Br. J. Cancer 81(3), 520–527 (1999).
•• Preclinical study demonstrating ultrasound as a noninvasive and effective modality to detect apoptotic cell death to anticancer
therapy. It formed the foundation for subsequent studies of using ultrasound for predicting and monitoring treatment response.
future science group 10.2144/fsoa-2020-0073
Research Article Tran, Suraweera, Quiaoit et al.
12. Kolios MC, Czarnota GJ, Lee M, Hunt JW, Sherar MD. Ultrasonic spectral parameter characterization of apoptosis. Ultrasound Med.
Biol. 28(5), 589–597 (2002).
13. Sadeghi-Naini A, Sannachi L, Tadayyon H et al. Chemotherapy-response monitoring of breast cancer patients using quantitative
ultrasound-based intra-tumour heterogeneities. Sci. Rep. 7(1), 1–12 (2017).
14. Sannachi L, Gangeh M, Tadayyon H et al. Response monitoring of breast cancer patients receiving neoadjuvant chemotherapy using
quantitative ultrasound, texture, and molecular features. PLoS ONE 13(1), 1–18 (2018).
• In 96 patients with breast cancer receiving neoadjuvant chemotherapy, quantitative ultrasound (QUS) scans were performed
during week 1, 4 and 8 of treatment. Machine-learning algorithm using spectral, texture and molecular features was able to
predict the response to chemotherapy with accuracies over 80% at weeks 4 and 8.
15. Tadayyon H, Sadeghi-Naini A, Czarnota GJ. Noninvasive characterization of locally advanced breast cancer using textural analysis of
quantitative ultrasound parametric images. Transl. Oncol. 7(6), 759–767 (2014).
• QUS can predict the response in patients with locally advanced breast cancer before starting neoadjuvant chemotherapy.
16. Slootweg PJ, Richardson M. Chapter 2 - Squamous cell carcinoma of the upper aerodigestive system. In: Diagnostic Surgical Pathology of
the Head and Neck. Gnepp DR (Ed.). Elsevier Inc, PA, USA, 45–110 (2009).
17. Winquist E, Agbassi C, Meyers B, Yoo J, Chan K. A quality initiative of the Program in Evidence-Based Care (PEBC), Cancer Care
Ontario (CCO). Systemic Therapy in the Curative Treatment of Head and Neck Squamous Cell Cancer. 1–5 (2017).
18. Lacchetti C, Waldron J, Cripps C, Gilbert R. A quality initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario
(CCO). Routine HPV Testing in Head and Neck Squamous Cell Carcinoma. ON, Canada (2013).
19. Tinmouth J, Kennedy E, Baron D et al. A quality initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario
(CCO). Guideline for colonoscopy quality assurance in Ontario: EBS development methods and external review process. Cancer Care
Ontario (CCO) 28(5), 21–82 (2014).
20. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
Eur. J. Cancer 45(2), 228–247 (2009).
21. Tadayyon H, Sannachi L, Gangeh M et al. Quantitative ultrasound assessment of breast tumor response to chemotherapy using a
multi-parameter approach. Oncotarget 7(29), 45094–45111 (2016).
22. Oelze ML, Brien WDO. Frequency-dependent attenuation-compensation functions for ultrasonic signals backscattered from random
media. J. Acoust. Soc. Am. 111(5), 2308–2319 (2002).
23. Labeyed Y, Bigelow TA. Estimating the total ultrasound attenuation along the propagation path by applying multiple filters to
backscattered echoes from a single spherically focused source. J Acoust. Soc. Am. 128(5), 3232–3238 (2010).
24. Wear KA, Wagner RF, Garra BS. High resolution ultrasonic backscatter coefficient estimation based on autoregressive spectral estimation
using Burg’s algorithm. IEEE Trans. Med. Imaging 13(3), 500–507 (1994).
25. Haralick R, Shanmugan K, Dinstein I. Textural features for image classification. IEEE Trans. Syst. Man Cybern. 3, 610–621 (1973).
26. Tsui P-H, Liao Y-Y, Kuo W-H et al. Classification of scattering media within benign and malignant breast tumors based on ultrasound
texture-feature-based and Nakagami-parameter images. Med. Phys. 38(4), 2198–2207 (2011).
27. Nutting CM, Morden JP, Harrington KJ et al. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck
cancer (PARSPORT): a Phase III multicentre randomised controlled trial. Lancet Oncol. 12(2), 127–136 (2011).
28. Epstein JB, Robertson M, Emerton S, Phillips N, Stevenson-Moore P. Quality of life and oral function in patients treated with radiation
therapy for head and neck cancer. Head Neck 23(5), 389–398 (2001).
29. Ringash J. Quality of life in head and neck cancer: where we are, and where we are going. Int. J. Radiat. Oncol. Biol. Phys. [Internet]
97(4), 662–666 (2017).
30. Lizzi FL, Astor M, Liu T, Deng C, Coleman DJ, Silverman RH. Ultrasonic spectrum analysis for tissue assays and therapy evaluation.
Int. J. Imaging Syst. Technol. 8(1), 3–10 (1997).
31. Lizzi FL, King DL, Rorke MC et al. Comparison of theoretical scattering results and ultrasonic data from clinical liver examinations.
Ultrasound Med. Biol. 14(5), 377–385 (1988).
32. Banihashemi B, Vlad R, Debeljevic B, Giles A, Kolios MC, Czarnota GJ. Ultrasound imaging of apoptosis in tumor response: novel
preclinical monitoring of photodynamic therapy effects. Cancer Res. 68(20), 8590–8596 (2008).
33. Vlad RM, Brand S, Giles A, Kolios MC, Czarnota GJ. Quantitative ultrasound characterization of responses to radiotherapy in cancer
mouse models. Clin. Cancer Res. 15(6), 2067–2075 (2009).
• Ultrasound spectral parameters were used to detect responses to radiotherapy in three mouse models of head and neck cancer.
34. Labyed Y, Bigelow TA. A theoretical comparison of attenuation measurement techniques from backscattered ultrasound echoes. J.
Acoust. Soc. Am. 129(4), 2316–2324 (2011).
35. Fujii Y, Taniguchi N, Itoh K et al. A new method for attenuation coefficient measurement in the liver. J. Ultrasound Med. 21(7),
783–788 (2002).
10.2144/fsoa-2020-0073 Future Sci. OA (2020) FSO624 future science group
QUS in response monitoring for head-neck malignancies Research Article
36. Nam K, Zagzebski JA, Hall TJ. Quantitative assessment of in vivo breast masses using ultrasound attenuation and backscatter. Ultrason.
Imaging 35(2), 146–161 (2013).
37. Lizzi FL, Ostromogilsky M, Feleppa EJ, Rorke MC, Yaremko MM. Relationship of ultrasonic spectral parameters to features of tissue
microstructure. IEEE Trans. Ultrason. Ferroelectr. Freq. Control 34(3), 319–329 (1987).
38. Sannachi L, Tadayyon H, Sadeghi-Naini A et al. Noninvasive evaluation of breast cancer response to chemotherapy using quantitative
ultrasonic backscatter parameters. Med. Image Anal. 20(1), 224–236 (2015).
39. Tadayyon H, Sadeghi-Naini A, Czarnota GJ. Noninvasive characterization of locally advanced breast cancer using textural analysis of
quantitative ultrasound parametric images. Transl. Oncol. 7(6), 759–767 (2014).
40. Sadeghi-Naini A, Suraweera H, Tran WT et al. Breast-lesion characterization using textural features of quantitative ultrasound
parametric maps. Sci. Rep. 7(1), 1–10 (2017).
41. Tran WT, Suraweera H, Quaioit K et al. Predictive quantitative ultrasound radiomic markers associated with treatment response in head
and neck cancer. FutureSci. OA 6(1), 1–17 (2019).
• Shows the efficacy of preradiation QUS and machine learning in predicting the response to treatment at 3months in 32 patients.
42. Giraud P, Giraud P, Gasnier A et al. Radiomics and machine learning for radiotherapy in head and neck cancers. Front. Oncol. 9(March),
1–13 (2019).
43. Cao Y, Popovtzer A, Li D et al. Early prediction of outcome in advanced head and alterations during therapy: a prospective study. Int. J.
Radiat. Oncol. Biol. Phys. 72(5), 1287–1290 (2013).
44. King AD, Kwok F, Mo F, Vlantis AC, Orl FCSSA, Ahuja AT. Head and neck squamous cell carcinoma: diagnostic performance of
diffusion-weighted MR imaging for the prediction of treatment. Radiology 266(2), 531–538 (2013).
45. Abdel Razek AAK. Arterial spin labelling and diffusion-weighted magnetic resonance imaging in differentiation of recurrent head and
neck cancer from post-radiation changes. J. Laryngol. Otol. 132(10), 923–928 (2018).
46. Razek AAKA, Gaballa G, Ashamalla G, Alashry MS, Nada N. Dynamic susceptibility contrast perfusion-weighted magnetic resonance
imaging and diffusion-weighted magnetic resonance imaging in differentiating recurrent head and neck cancer from postradiation
changes. J. Comput. Assist. Tomogr. 39(6), 849–854 (2015).
47. Abdel Razek AAK. Diffusion tensor imaging in differentiation of residual head and neck squamous cell carcinoma from post-radiation
changes. Magn. Reson. Imaging 54(August), 84–89 (2018).
48. Kuno XH, Garg XN, Qureshi XMM et al. Head & neck CT texture analysis of cervical lymph nodes on contrast-enhanced [18 F]
FDG-PET / CT images to differentiate nodal metastases from reactive lymphadenopathy in HIV-positive patients with head and neck
squamous cell carcinoma. Head Neck 40(3), 543–550 (2019).
49. Hauser T, Essig M, Jensen A et al. Prediction of treatment response in head and neck carcinomas using IVIM-DWI: evaluation of lymph
node metastasis. Eur. J. Radiol. 83(5), 783–787 (2014).
50. Brizel DM, Dodge RK, Clough RW, Dewhirst MW. Oxygenation of head and neck cancer: changes during radiotherapy and impact on
treatment outcome. Radiother. Oncol. 53(2), 113–117 (1999).
51. Goguen LA, Chapuy CI, Li Y, Zhao SD, Annino DJ. Neck dissection after chemoradiotherapy. Arch. Otolaryngol. Head Neck Surg.
136(11), 1071–1077 (2010).
52. Sannachi L, Gangeh M, Naini A-S et al. Quantitative ultrasound monitoring of breast tumour response to neoadjuvant chemotherapy:
comparison of results among clinical scanners. Ultrasound Med. Biol. [Internet] 46(5), 1142–1157 (2020).
53. Thibault G, Tudorica A, Afzal A et al. DCE-MRI texture features for early prediction of breast cancer therapy response. Tomography 3(1),
23–32 (2017).
future science group 10.2144/fsoa-2020-0073
